ASX healthcare hammered! Where’s the bottom for CSL, COH, RMD and TLX?
The article says ASX healthcare stocks fell sharply in FY26, with the Health Care sector down 36.1% and CSL, Cochlear, Resmed and Telix each down over 30% to 12 months. It compares Refinitiv consensus EPS forecasts for FY26-28 and UBS EPS estimates, noting earnings are not forecast to collapse as much as share prices. UBS cited sector picks in a 24 July 2026 note.
How this was made
The 30-second read
Why it matters
For traders, the actionable takeaway is the valuation-versus-earnings disconnect: price declines may continue even when consensus EPS growth is still positive, until guidance credibility and discount-rate assumptions stabilize.
Market read
This is a multi-stock valuation narrative using consensus and UBS EPS forecasts to explain why healthcare prices fell far more than earnings forecasts imply.
What to watch
The article does not quantify duration of multiple compression, liquidity/positioning effects, or whether currency, discount rates, or regulatory/product risks are driving the re-pricing.
Background
The piece argues ASX healthcare’s FY26 drawdown is not explained by consensus EPS collapsing, and instead points to “multiple compression” plus recent guidance downgrades (especially CSL and COH).
Ticker impact
RMD is described as forecast to grow earnings 8% in both FY26 and FY27 while the stock fell about 32% over 12 months.
Downside risk persists if multiples keep compressing; upside depends on whether earnings growth is reaffirmed.
Article provides the earnings-growth vs price-discount comparison but offers less company-specific downgrade detail than CSL/COH, reducing conviction.
TLX is presented as having a small earnings base scaling up rapidly (FY27E +400% EPS) while the stock is down about 33% over 12 months.
Potential for sharp mean reversion if the market re-rates early-stage earnings, but volatility remains high.
Body shows extreme forecast EPS growth rates but does not provide additional fundamental catalysts beyond the multiple-compression framework.
Market effects
If the thesis is correct, ASX healthcare weakness may persist until bond-yield sensitivity and company-specific guidance credibility improve.
Australia-focused read-through: healthcare’s defensive bid may be less reliable when multiples compress with higher yields.
Generalizable to global healthcare quality compounders where rising yields and downgrade cycles can drive multiple compression.
Counterpoint
The “no earnings collapse” framing may understate forward risk, such as margin pressure, product-cycle timing, or one-off items that could later force larger estimate cuts.
Key entities
- companyCSL
ASX healthcare bellwether cited for a large 12-month share price decline despite consensus EPS growth into FY28, with UBS EPS downgrades and guidance cut referenced.
- companyCochlear
Cited for a steep 12-month price fall alongside a forecast FY26 EPS decline followed by FY27 snap-back, framed as multiple compression after downgrades.
- companyResMed
Cited for ongoing forecast EPS growth while the stock fell, framed as valuation compression rather than earnings collapse.
- companyTelix Pharmaceuticals
Cited for a small earnings base scaling up rapidly in forecasts while the stock is down, framed as valuation-driven weakness.
- investment bankUBS
Used as the source of more cautious FY26-FY27 EPS forecasts and sector research referenced in the article.
